Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer
- PMID: 24416563
- PMCID: PMC3863222
- DOI: 10.1016/j.rpor.2012.12.006
Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer
Abstract
Background: To make a radiobiological comparison, for high risk prostate cancer (T3a, PSA > 20 ng/ml or Gleason > 7) of two radiotherapy treatment techniques. One technique consists of a treatment in three phases of the pelvic nodes, vesicles and prostate using a conventional fractionation scheme of 2 Gy/fraction (SIMRT). The other technique consists of a treatment in two phases that gives simultaneously different dose levels in each phase, 2 Gy/fraction, 2.25 Gy/fraction and 2.5 Gy/fraction to the pelvic nodes, vesicles and prostate, respectively (SIBIMRT).
Materials and methods: The equivalent dose at fractionation of 2 Gy (EQD2), calculated using the linear quadratic model with α/β prostate = 1.5 Gy, was the same for both treatment strategies. For comparison the parameters employed were D95, mean dose and Tumour Control Probabilities for prostate PTV and D15, D25, D35, D50, mean dose and Normal Tissue Complication Probabilities for the rectum and bladder, with physical doses converted to EQD2. Parameters were obtained for α/β prostate = 1.5, 3 and 10 Gy and for α/β oar = 1, 2, 3, 4, 6 and 8.
Results: For prostate PTV, both treatment strategies are equivalent for α/β prostate = 1.5 Gy but for higher α/β prostate, EQD2 and TCP, decrease for the SIBIMRT technique. For the rectum and bladder when α/β oar ≤ 2 Gy, EQD2 and NTCP are lower for the SIMRT technique or equal in both techniques. For α/β oar ≥ 2-3 Gy, EQD2 and NTCP increase for the SIMRT treatment.
Conclusions: A comparison between two radiotherapy techniques is presented. The SIBIMRT technique reduces EQD2 and NTCP for α/β oar from 2 to 8 Gy.
Keywords: Equivalent dose at fractionation of 2 Gy (EQD2); NTCP; Prostate; Radiobiology; Simultaneous integrated boost.
Figures




Similar articles
-
SU-E-T-02: Radiobiological Comparison of Two Treatment Schemas in IMRT Prostate Radiotherapy.Med Phys. 2012 Jun;39(6Part9):3702. doi: 10.1118/1.4735056. Med Phys. 2012. PMID: 28519019
-
Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.J Cancer Res Ther. 2009 Apr-Jun;5(2):78-84. doi: 10.4103/0973-1482.52789. J Cancer Res Ther. 2009. PMID: 19542662
-
Comparison of intensity-modulated radiotherapy and forward-planning dynamic arc therapy techniques for prostate cancer.J Appl Clin Med Phys. 2008 Oct 24;9(4):37-56. doi: 10.1120/jacmp.v9i4.2783. J Appl Clin Med Phys. 2008. PMID: 19020481 Free PMC article.
-
The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.Radiat Oncol. 2018 May 16;13(1):96. doi: 10.1186/s13014-018-1040-z. Radiat Oncol. 2018. PMID: 29769103 Free PMC article. Review.
-
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.Acta Oncol. 2005;44(3):265-76. doi: 10.1080/02841860410002824. Acta Oncol. 2005. PMID: 16076699 Review.
Cited by
-
Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial.BJU Int. 2020 Feb;125(2):215-225. doi: 10.1111/bju.14925. Epub 2019 Nov 8. BJU Int. 2020. PMID: 31614071 Free PMC article. Clinical Trial.
-
SBRT and extreme hypofractionation: A new era in prostate cancer treatments?Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):411-6. doi: 10.1016/j.rpor.2014.09.005. Epub 2014 Oct 22. Rep Pract Oncol Radiother. 2015. PMID: 26696780 Free PMC article.
-
Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer.Life (Basel). 2022 Mar 9;12(3):394. doi: 10.3390/life12030394. Life (Basel). 2022. PMID: 35330145 Free PMC article.
-
Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients.Radiat Oncol J. 2022 Jun;40(2):151-161. doi: 10.3857/roj.2021.01032. Epub 2022 Jun 20. Radiat Oncol J. 2022. PMID: 35796118 Free PMC article.
-
Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition.Radiat Oncol. 2020 Oct 20;15(1):242. doi: 10.1186/s13014-020-01683-4. Radiat Oncol. 2020. PMID: 33081804 Free PMC article.
References
-
- Wang J.Z., Guerrero M., Li X.A. How low is the a/b ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;55:194–203. - PubMed
-
- Fowler J., Chappell R., Ritter M. Is a/b for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021–1031. - PubMed
-
- Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 2007;19:289–301. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous